ERBB2 and non-small cell lung carcinoma: Females with advanced NSCLC had significantly more alterations in all assessed EGFR mutations [i.e., ex19 del (9.55% vs. 5.86%; p < 0.0001), ex20 ins (1.25% vs. 0.95%; p = 0.0139), G719X (0.96% vs. 0.59%; p = 0.0003), L858R (6.81% vs. 3.96%; p < 0.0001), T790M (1.08% vs. 0.57%; p < 0.0001), S768I (0.47% vs. 0.25%; p = 0.0013), and L861Q (0.58% vs. 0.34%; p = 0.002)], KRAS G12C (7.10% vs. 6.41%; p = 0.0169), and ERBB2 ex20 ins (1.40% vs. 1.00%; p = 0.0012) compared to the males.